Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 janv. 2026 08h30 HE | Source: GRI Bio, Inc.

GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures

Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio,...
21 janv. 2026 16h01 HE | Source: GRI Bio, Inc.

GRI Bio Announces Reverse Stock Split

GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
14 janv. 2026 08h05 HE | Source: Scienture Holdings, Inc.

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for...
13 janv. 2026 12h30 HE | Source: Custom Market Insights

[Latest] Global Neurocosmetics Market Size/Share Worth USD 3.5 Billion by 2034 at a 8.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neurocosmetics Market Size, Trends and Insights By Product Type (Body Care, Face...
12 janv. 2026 08h36 HE | Source: Moleculin Biotech, Inc.

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE...
08 janv. 2026 08h00 HE | Source: GRI Bio, Inc.

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE...
24 déc. 2025 11h30 HE | Source: WORK Medical Technology Group LTD

WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary,...
19 déc. 2025 09h00 HE | Source: Jyong Biotech Ltd.

Jyong Biotech Responds to Share Price and Volume Movement

New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”) notes the recent fluctuation in its share price and the increased...
18 déc. 2025 08h45 HE | Source: Biofrontera Inc.

Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted...
17 déc. 2025 08h31 HE | Source: Moleculin Biotech, Inc.

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune...

Page suivante